Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Applied and Environmental Microbiology|August 7, 2003
Characterization of Escherichia coli O157:H7 from downer and healthy dairy cattle in the upper Midwest region of the United StatesC M Byrne, I Erol, J E Call, et al.
Neurosurgical Review|January 14, 2026
Combining 3D printing and elastographic characterization: A novel sphenoid wing meningioma simulation model for neurosurgical trainingSifian Al-Hamid, Fränze Grellmann, Julius Reiser, et al.
Frontiers in Immunology|April 29, 2026
Immune architecture of colorectal cancer brain metastases: spatial TAM heterogeneity and PD-L1 dynamicsLisa Marie Grape, Benjamin Hanke, Belal Neyazi, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|August 11, 2012
Vascularised local and free flaps in anterior skull base reconstructionThomas K Hoffmann, Nicolai El Hindy, Oliver M Müller, et al.
Frontiers in Immunology|November 22, 2021
Generation of an NFκB-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell TherapyLoreen Sophie Rudek, Katharina Zimmermann, Melanie Galla, et al.
Cancers|February 12, 2020
Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible CytokinesKatharina Zimmermann, Johannes Kuehle, Anna Christina Dragon, et al.
Clinical Neurology and Neurosurgery|August 3, 2021
Frequency of actionable molecular drivers in lung cancer patients with precocious brain metastasesBenjamin Hanke, Stephanie T Jünger, Elmar Kirches, et al.
Frontiers in Pharmacology|October 10, 2024
Muscarinic receptor drug trihexyphenidyl can alter growth of mesenchymal glioblastoma in vivoRenfei Du, Ahmed Y Sanin, Wenjie Shi, et al.
Acta Neuropathologica|October 15, 2017
Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesisUlrike Beyer, Frank Brand, Helge Martens, et al.
BMC Cancer|February 20, 2025
The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastomaMatthias Schneider, Anna-Laura Potthoff, Yahya Ahmadipour, et al.
Pageof 13